Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Carbon Biosciences has raised $38.0M in total funding. The most recent round was Series A. The last funding was announced in June 2022.
Carbon Biosciences's investors include Longwood Fund, UTokyo Innovation Platform, DHVC, Agent Capital, Cystic Fibrosis Foundation.
Carbon Biosciences is headquartered in Lexington, United States.
Carbon Biosciences is a biotech company that engages in the novel parvovirus gene therapy.
Carbon Biosciences is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Carbon Biosciences — Funding & Investors." VCBacked, June 21, 2022, https://www.vcbacked.co/company/carbon-biosciences. Accessed August 14, 2026.
VCBacked. (2022). Carbon Biosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/carbon-biosciences
{{cite web |title=Carbon Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/carbon-biosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated